Biotransformacja leków: Przegląd

Drug biotransformation, also called drug metabolism, chemically alters drugs to facilitate their elimination from the body and terminate their action. This process converts lipophilic drugs into polar, water-soluble products that are readily excreted via urine or bile. Biotransformation detoxifies xenobiotics, activates prodrugs, and prevents drug accumulation, reducing toxicity risk and ensuring patient safety.

Phase I reactions introduce or unmask polar functional groups through oxidation, reduction, and hydrolysis, increasing water solubility. Phase II reactions further enhance solubility by conjugating phase I products with small polar molecules like glucuronic acid, sulfate, glycine, and glutathione, forming highly water-soluble metabolites ready for excretion.

The liver is the primary site for drug metabolism, containing abundant drug-metabolizing enzymes. However, the lungs, kidneys, intestines, placenta, and skin also contribute to biotransformation. Microsomal enzymes in the liver's endoplasmic reticulum catalyze most reactions, while non-microsomal enzymes in the cytoplasm and mitochondria play subsidiary roles.

Phase II conjugation reactions include glucuronidation, sulfation, acetylation, methylation, and glutathione conjugation. These reactions attach small polar molecules to drugs or their phase I metabolites, dramatically increasing water solubility. Each conjugation type targets specific functional groups, ensuring efficient conversion of diverse drug structures into excretable metabolites.

Biotransformation converts lipophilic drugs into hydrophilic, water-soluble metabolites through phase I and phase II reactions. This increased water solubility prevents reabsorption in the lipophilic environment of renal tubules, ensuring efficient excretion via urine or bile. The process is essential for terminating drug action and preventing toxic accumulation.

While biotransformation generally detoxifies drugs, it can also form reactive metabolites that cause adverse effects and toxicity. These reactive intermediates may bind to cellular proteins or DNA, potentially causing tissue damage or triggering immune responses. Understanding how physicochemical and chemical properties influence reactive metabolite formation is critical for drug safety assessment.

Codeine is converted to morphine through biotransformation, demonstrating how metabolism can activate a prodrug into a more potent form. This conversion involves phase I reactions that modify the drug's chemical structure, followed by phase II conjugation reactions that enhance water solubility, enabling efficient excretion while the active metabolite exerts therapeutic effects.